The four-year-old biotech raised about $75 million in a Series A round that involved nine venture capital firms.

Actithera has secured $75.5 million in an oversubscribed Series A round to support the clinical development of its lead ...

PET-CT scans combine structural and functional imaging to detect diseases early. This technology improves diagnosis accuracy ...

Radiopharmaceutical biotech Actithera today announced the close of an oversubscribed $75.5 million Series A financing round.

BIO investing in unique radiopharmaceutical platform company, developing radioligands with prolonged tumour retention ...

Actithera, a radiopharmaceutical biotech pioneering precision radioligand therapies, has closed an oversubscribed Series A ...

Skin health experts debunk collagen myths, like whether or not collagen supplements really work, and all the ways you can ...

Lantheus Holdings Inc. (NASDAQ:LNTH) is one of the most undervalued US stocks according to analysts. On June 20, Lantheus ...

BIO investing in unique radiopharmaceutical platform company, developing radioligands with prolonged tumour retention Series A was co-led by 4BIO Capital, founding investor M Ventures, Hadean Ventures ...

Take a closer look at the radiopharma new wave as Nuclidium and Actithera raise big to develop their platforms.

This new article publication from Acta Pharmaceutica Sinica B, discusses a high clinically translatable strategy to anti-aging using hyaluronic acid and silk fibroin co-crosslinked hydrogels as dermal ...